Assessing clinical and functional outcomes in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial

Marvin S. Swartz, Diana O. Perkins, T. Scott Stroup, Joseph Patrick McEvoy, Jennifer M. Nieri, David C. Haak

Research output: Contribution to journalReview article

81 Citations (Scopus)

Abstract

Schizophrenia is a symptomatically heterogeneous disorder characterized by the presence of positive and negative symptoms, and variable impairment in community functioning. Given the diversity of symptom presentations and functioning associated with schizophrenia, one of the key challenges facing the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial was the selection of efficient assessment measures appropriate to a community-based effectiveness trial. This article describes the rationale for the measurement approach adopted for the trial, provides a brief overview of the selected measures, and describes the process of training assessment raters for a large and geographically dispersed study group.

Original languageEnglish (US)
Pages (from-to)33-43
Number of pages11
JournalSchizophrenia Bulletin
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Antipsychotic Agents
Schizophrenia
Clinical Trials
Process Assessment (Health Care)

Keywords

  • Functional assessment
  • Outcome measures
  • Psychopathology assessment
  • Schizophrenia treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Assessing clinical and functional outcomes in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial. / Swartz, Marvin S.; Perkins, Diana O.; Stroup, T. Scott; McEvoy, Joseph Patrick; Nieri, Jennifer M.; Haak, David C.

In: Schizophrenia Bulletin, Vol. 29, No. 1, 01.01.2003, p. 33-43.

Research output: Contribution to journalReview article

Swartz, Marvin S. ; Perkins, Diana O. ; Stroup, T. Scott ; McEvoy, Joseph Patrick ; Nieri, Jennifer M. ; Haak, David C. / Assessing clinical and functional outcomes in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial. In: Schizophrenia Bulletin. 2003 ; Vol. 29, No. 1. pp. 33-43.
@article{2289fd8d62534870a4dca13dc5175516,
title = "Assessing clinical and functional outcomes in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial",
abstract = "Schizophrenia is a symptomatically heterogeneous disorder characterized by the presence of positive and negative symptoms, and variable impairment in community functioning. Given the diversity of symptom presentations and functioning associated with schizophrenia, one of the key challenges facing the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial was the selection of efficient assessment measures appropriate to a community-based effectiveness trial. This article describes the rationale for the measurement approach adopted for the trial, provides a brief overview of the selected measures, and describes the process of training assessment raters for a large and geographically dispersed study group.",
keywords = "Functional assessment, Outcome measures, Psychopathology assessment, Schizophrenia treatment",
author = "Swartz, {Marvin S.} and Perkins, {Diana O.} and Stroup, {T. Scott} and McEvoy, {Joseph Patrick} and Nieri, {Jennifer M.} and Haak, {David C.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1093/oxfordjournals.schbul.a006989",
language = "English (US)",
volume = "29",
pages = "33--43",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Assessing clinical and functional outcomes in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial

AU - Swartz, Marvin S.

AU - Perkins, Diana O.

AU - Stroup, T. Scott

AU - McEvoy, Joseph Patrick

AU - Nieri, Jennifer M.

AU - Haak, David C.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Schizophrenia is a symptomatically heterogeneous disorder characterized by the presence of positive and negative symptoms, and variable impairment in community functioning. Given the diversity of symptom presentations and functioning associated with schizophrenia, one of the key challenges facing the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial was the selection of efficient assessment measures appropriate to a community-based effectiveness trial. This article describes the rationale for the measurement approach adopted for the trial, provides a brief overview of the selected measures, and describes the process of training assessment raters for a large and geographically dispersed study group.

AB - Schizophrenia is a symptomatically heterogeneous disorder characterized by the presence of positive and negative symptoms, and variable impairment in community functioning. Given the diversity of symptom presentations and functioning associated with schizophrenia, one of the key challenges facing the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial was the selection of efficient assessment measures appropriate to a community-based effectiveness trial. This article describes the rationale for the measurement approach adopted for the trial, provides a brief overview of the selected measures, and describes the process of training assessment raters for a large and geographically dispersed study group.

KW - Functional assessment

KW - Outcome measures

KW - Psychopathology assessment

KW - Schizophrenia treatment

UR - http://www.scopus.com/inward/record.url?scp=0037771503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037771503&partnerID=8YFLogxK

U2 - 10.1093/oxfordjournals.schbul.a006989

DO - 10.1093/oxfordjournals.schbul.a006989

M3 - Review article

VL - 29

SP - 33

EP - 43

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 1

ER -